
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
30 June 2023
New book ‘Bronty’s Battle Cry’ supports Leukaemia UK
‘Bronty’s Battle Cry,’ an inspiring new picture book written by award-winning children’s author and young person’s counsellor, Hannah Peckham, has recently launched and Leukaemia UK are delighted that some of…
3 February 2022
New analysis reveals the stark disparities in cancer rates between ethnic groups
The Cancer Research UK study demonstrates the importance of understanding the differences and inequalities in cancer and to highlight where improvements in survival, treatment and care can be made.
27 August 2020
Leukaemia UK appoints new CEO
The trustees of Leukaemia UK are delighted to announce that they have appointed Fiona Hazell as CEO of Leukaemia UK. Fiona brings a strong track record in not-for-profit leadership, starting her role on 9th September 2020.
27 September 2024
Leukaemia UK calls upon government to increase blood testing capacity
Together with Leukaemia Care, we’re calling on the new Secretary of State for Health and Social Care to focus on ‘business as usual’ primary care testing alongside innovation, amid concerns…